Level 2

Company Announcements

Additional listing

Related Companies

By LSE RNS

RNS Number : 9549A
Sinclair Pharma PLC
30 March 2017
 

Sinclair Pharma plc

 

Additional listing

 

London, 30 March 2017 Sinclair Pharma plc (SPH.L), ("Sinclair" or the "Company") the international aesthetics company, announces that 1,570,510 new ordinary shares of 1p each (the "New Ordinary Shares") have been issued and allotted to Christophe Foucher, former COO, in settlement of his severance package as previously announced on 1 September 2016.

 

Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on 5 April 2017 and, when issued, the New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares.

 

Following admission of the New Ordinary Shares, Sinclair will have 503,768,952 ordinary shares of 1p in issue.

 

This announcement contains inside information. The person responsible for arranging for the release of this announcement on behalf of Sinclair is Alan Olby, Chief Financial Officer.

 

For further information please contact:

 

Sinclair Pharma plc

Tel: +44 (0) 20 7467 6920

Chris Spooner
Alan Olby

Andy Crane




Peel Hunt LLP (NOMAD and Joint Broker)

Tel: +44 (0) 20 7418 8900

James Steel
Oliver Jackson




 RBC Capital Markets (Joint Broker)

Tel: +44 (0) 20 76534000

Marcus Jackson
Laura White




Media enquiries


FTI Consulting

Tel: +44 (0) 203 727 1000

Ben Atwell
Brett Pollard


 

Notes to Editors:

 

About Sinclair Pharma plc 

Sinclair Pharma plc is an international company operating in the fast growth, high gross margin, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. The Company is planning entry to multiple new geographic markets and line extension launches over the next few years. Sinclair has an established sales and marketing presence in the leading EU markets and Brazil, and a network of international distributorsFor more information, please visit www.sinclairpharma.com

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ALSDMGZFZLNGNZZ

Top of Page